Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert M Califf

Showing results (341-350 of 770) with videos related to

Pageof 77
Sort By:
The American Journal of Medicine|January 13, 2004
Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromesAbdallah G Rebeiz, Matthew T Roe, John H Alexander, et al.
The Canadian Journal of Cardiology|April 5, 2003
Impact of on-site cardiac interventional facilities on management and outcome of patients with acute coronary syndromesFadi H Khadour, Yuling Fu, Wei-Ching Chang, et al.
The American Journal of Cardiology|October 24, 2007
Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial)Monica R Shah, Vic Hasselblad, Gudaye Tasissa, et al.
The American Journal of Cardiology|September 22, 2007
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials)Sabina A Murphy, Christopher P Cannon, Stephen D Wiviott, et al.
JAMA Internal Medicine|May 24, 2013
Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.govBradford R Hirsch, Robert M Califf, Steven K Cheng, et al.
European Heart Journal|June 4, 2008
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trialRenato D Lopes, Karen P Alexander, Gretchen Marcucci, et al.
Clinical Pharmacology and Therapeutics|April 7, 2021
When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?Jessica M Franklin, Richard Platt, Nancy A Dreyer, et al.
JAMA|April 14, 2005
Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomesRajendra H Mehta, John H Alexander, Frans Van de Werf, et al.
Hypertension (Dallas, Tex. : 1979)|May 9, 2018
Can We End the Salt Wars With a Randomized Clinical Trial in a Controlled Environment?Daniel W Jones, Friedrich C Luft, Paul K Whelton, et al.
Critical Pathways in Cardiology|May 7, 2009
Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH RegistryKim A Eagle, Alan T Hirsch, Robert M Califf, et al.
Pageof 77

Showing results (341-350 of 770) with videos related to

Sort By:
Pageof 77
The American Journal of Medicine|January 13, 2004
Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromesAbdallah G Rebeiz, Matthew T Roe, John H Alexander, et al.
The Canadian Journal of Cardiology|April 5, 2003
Impact of on-site cardiac interventional facilities on management and outcome of patients with acute coronary syndromesFadi H Khadour, Yuling Fu, Wei-Ching Chang, et al.
The American Journal of Cardiology|October 24, 2007
Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial)Monica R Shah, Vic Hasselblad, Gudaye Tasissa, et al.
The American Journal of Cardiology|September 22, 2007
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials)Sabina A Murphy, Christopher P Cannon, Stephen D Wiviott, et al.
JAMA Internal Medicine|May 24, 2013
Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.govBradford R Hirsch, Robert M Califf, Steven K Cheng, et al.
European Heart Journal|June 4, 2008
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trialRenato D Lopes, Karen P Alexander, Gretchen Marcucci, et al.
Clinical Pharmacology and Therapeutics|April 7, 2021
When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?Jessica M Franklin, Richard Platt, Nancy A Dreyer, et al.
JAMA|April 14, 2005
Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomesRajendra H Mehta, John H Alexander, Frans Van de Werf, et al.
Hypertension (Dallas, Tex. : 1979)|May 9, 2018
Can We End the Salt Wars With a Randomized Clinical Trial in a Controlled Environment?Daniel W Jones, Friedrich C Luft, Paul K Whelton, et al.
Critical Pathways in Cardiology|May 7, 2009
Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH RegistryKim A Eagle, Alan T Hirsch, Robert M Califf, et al.
Pageof 77